BioExpert Network – Experts network to analyse Biotech or Medtech startups

BioExpert Network

Continue reading

Biotechnology Marketing

Biotechnology Marketing

Medtech is a trending topic in the Startup World ! Biotech and Healthcare are booming, and lots of investors trust these subjects as highly potent and valuable. Not for short term investment, of course, but for long term, big profit investments. An important part of being successful or not for this kind of startups is related to Biotechnology Marketing. Will this startup be visible in the Biotech and Lifescience World ?

Some solutions exist enabling medtech startups or biotech companies to find customers for innovative and technical products. For instance, Bio Leads is a new service proposing full list of potential customer depending on customer’s criteria. Define your keywords, geographical restriction, etc… and you will receive a full list of scientists corresponding to your criteria.

More information on Biotech Marketing : BioLeads on Twitter


Biotechnology Marketing

Biotechnology Marketing – Biotech Marketing – Lifescience Marketing – Biopharma Marketing – Pharma Marketing – Medtech Marketing – Science Marketing –  Biotechnology Mktg – Biotech Mktg – Lifescience Mktg – Biopharma Mktg – Pharma Mktg – Medtech Mktg – Science Mktg – Marketing Medtech Startups – Marketing Biotech Startups – Marketing Biopharma Startups – Marketing Pharma Startups – Marketing Science Startups

Biotechnology Marketing – Biotech Marketing – Lifescience Marketing – Biopharma Marketing – Pharma Marketing – Medtech Marketing – Science Marketing –  Biotechnology Mktg – Biotech Mktg – Lifescience Mktg – Biopharma Mktg – Pharma Mktg – Medtech Mktg – Science Mktg – Marketing Medtech Startups – Marketing Biotech Startups – Marketing Biopharma Startups – Marketing Pharma Startups – Marketing Science Startups

Biotechnology Marketing – Biotech Marketing – Lifescience Marketing – Biopharma Marketing – Pharma Marketing – Medtech Marketing – Science Marketing –  Biotechnology Mktg – Biotech Mktg – Lifescience Mktg – Biopharma Mktg – Pharma Mktg – Medtech Mktg – Science Mktg – Marketing Medtech Startups – Marketing Biotech Startups – Marketing Biopharma Startups – Marketing Pharma Startups – Marketing Science Startups


Startup 365 – Biotech 365 : Marketing Medtech Startup , Biotechnology Marketing , Marketing Biotech Startup , Marketing Biopharma Startup , Marketing Pharma Startup , Marketing Science Startup , Marketing Medtech , Marketing Biotech , Marketing Biopharma , Marketing Pharma , Marketing Science , Biotechnology Marketing , Mktg Medtech , Mktg Biotech , Mktg Biopharma , Mktg Pharma , Mktg Science

Sectra – management and communication of all types of medical images

International medical imaging IT company Sectra announces that it has been awarded a group purchasing agreement
for dose tracking with Premier Inc. Effective July 2016, the new
agreement allows Premier members, at their discretion, to take advantage
of special pricing and terms pre-negotiated by Premier for dose
monitoring software.

Sectra DoseTrack™ is a complete web based solution for radiation dose
monitoring that gathers and reports dose data from all necessary sources
within the imaging department. Robust analysis capabilities for dose
optimization assist in the identification of needed actions such as
changing modalities for specific procedures, staff training or imaging
protocol revisions. Consideration of patient size and demographics allow
for effective organ dose calculations and patient risk assessment.

“This contract with Premier reflects the success we have had with Sectra
DoseTrack over the last three years. Our software flexibility and
customizations confirm our ongoing dedication to customer satisfaction”,
says Sectra North American President, Mikael Anden.

Premier is a leading healthcare improvement company, uniting an alliance
of approximately 3,600 U.S. hospitals and 120,000 other providers to
transform healthcare.

About this startup

The world needs more efficient healthcare and more secure communication.
Sectra plays a key role in meeting these needs. Sectra assists hospitals
throughout the world to enhance the efficiency of care, and authorities
and defense forces in Europe to protect society’s most sensitive
information. The company was founded in 1978, has its head office in
Linköping, Sweden, with subsidiaries in 14 countries, and operates
through partners worldwide. Sales in the 2015/2016 fiscal year totaled
SEK 1,073 million. The Sectra share is quoted on the Nasdaq Stockholm
exchange. For more information, visit

In the medical market, this company develops and sells IT solutions for the
management and communication of all types of medical images – primarily
in radiology, mammography, pathology and orthopaedics, as well as other
departments where medical images are used. Sectra has a strategic focus
on making cancer care more efficient. More than 1,700 hospitals, clinics
and imaging centers worldwide use Sectra’s systems daily. This makes
Sectra one of the world’s leading providers of IT solutions for managing
medical images and patient information. The company commands a
market-leading position in Sweden, Norway, the Netherlands and Portugal,
holds a prominent position in the UK and is growing in the US. Sectra
has delivered some of the largest installations of medical IT systems
worldwide and its systems have been installed in North America,
Scandinavia and most major countries in Europe and the Far East.

This information was brought to you by Cision

Management and communication of all types of medical images
Contacts :
Dr. Torbjörn Kronander, CEO and President
46 (0) 705
23 52 27
Marie Ekström Trägårdh
Executive Vice
President and President Imaging IT Solutions
(0)708 23 56 10

management and communication of all types of medical images


iPug – Global Digital Health

A network of New Zealand angel investors has helped launch iPug, a
digital health company that is transforming the way research and public
health campaigns are delivered, into the US market at the BIO
International Convention in San Francisco.

The investors, led by Hamilton-based property developer and investor,
Zane Beckett, have provided seed capital and Series A funding, playing a
significant role in the early-stage development of the company.

According to Beckett, iPug was a natural choice. “Digital health is hot
at the moment,” he said. “iPug has a clear path to market, amazing
partners and customers, and impressive technology.”

iPug, an Australian company now based in San Francisco, uses its
gamified, reward-based communications platform to deliver individualised
public health campaigns, and recruit and engage participants in research
studies and clinical trials. The mobile-friendly technology delivers the
right message, at the right time, on the right device with the right
reward incentive. This type of engagement has proven to save time, money
and has a higher success rate in influencing behavior as it relates to
public health.

Speaking on the emergence of digital health technology in the US and the
opportunity for iPug, Steve Huff, CEO and Co-Founder of iPug, said it
was an exciting time to be in digital health.

“Digital health funding is up, with over $900m in investment in Q1 of
this year. This represents a 50% year-on-year growth from the same time
last year. We have been pleased with our funding support from New
Zealand investors.”

After successfully launching in Australia and most notably developing
the injury prevention app Cool Runnings for the Center for Children’s
Burns and Trauma Research, University of Queensland, iPug sees
tremendous opportunity in the US to reduce public health costs,
effectively scale and deliver measurable results for public health

For media inquiries, please contact:

About iPug:

iPug is the world’s first mobile-friendly platform that transforms the
way research is conducted and how public health campaigns are delivered
through gamification.


for iPug
Priya Ghandikota

Coalesce Product Development – drug delivery devices


Coalesce Product Development - drug delivery devices

Another star is twinkling brightly in Cambridge UK’s world-leading galaxy of product design consultancies – providing innovation for global science & technology market leaders.

Coalesce Product Development, headed up by former Sagentia man Dave Ahern, has expanded into significant office and laboratory space at Edinburgh House on the St John’s Innovation Park. The business incubated within St John’s Innovation Centre and has now agreed a five-year lease for space at Edinburgh House totalling 3,796 sq ft in a deal negotiated by Savills.

Cambridge has created a cluster of tech product design consultancies that even the US cannot match. In fact US, Asian and European clients beat a path to Cambridge’s door to turn raw IP into prototypes and marketable products.

Coalesce specialises in drug delivery devices. Engineer Ahern splits his time between working on projects and running the business and has assembled a strong team of engineers. His particular expertise is in respiratory drug delivery devices, built up while working on and managing dry powder inhaler projects for, amongst others, Dey Pharmaceuticals, Chiesi, Novartis and Vectura.

He began his career designing bespoke bomb-disposal robots and then mice and trackballs for high volume manufacture in the Far East. From Logitech, he moved into consultancy with Scientific Generics (now Sagentia) and his focus changed mainly to the medical sector and eventually to drug delivery devices.

Over the past two decades, both as an independent consultant and then at Coalesce Product Development, he has worked on a variety of medical devices, ranging from a gamma knife for Elekta, thoracic surgery equipment for Covedien, an arthroscopic surgical device for Gyrus Medical and a hand-held magnetic probe for sentinel node biopsy procedures for Endomag.

Science Group plc, Sagentia’s parent company, is meanwhile hiring experienced operator Andrew Diston from fellow Cambridge consultancy Medicom Innovation Partner. Diston was also formerly at Cambridge Consultants and has been appointed group science & technology director and a member of the group executive board with effect from September.

He is currently executive VP at Medicom, where he has had global responsibility for the commercial development of the Danish and Cambridge based business. Medicom specialises in designing and developing advanced drug delivery and connected health systems. Prior to Medicom, he spent most of his career at Cambridge Consultants – ultimately as head of the medical technology design and development business.

Science Group comprises four operating businesses, the original and largest being Sagentia, the Cambridge-based science and technology consulting company.

Recent acquisitions by the group have expanded operations into additional vertical markets providing new opportunities for growth. The role of group science & technology director engages the science, engineering and innovation capabilities of the operating businesses to open up new market opportunities.

Science Group has just posted interim results for the six months to the end of June and increased revenue to £17.7 million from £14.1m in the first half of 2015. The adjusted operating profit of £2.5m compared to £2.4m last time. The company reports net cash and freehold property assets of £31.3m, ahead of this stage last year.

Coalesce Product Development – drug delivery devices

• PHOTOGRAPH SHOWS: Edinburgh House on St John’s Innovation Park

Coalesce Product Development – drug delivery devices

Owlstone – cancer breathalyser


Owlstone Billy Boyle

Owlstone Medical in Cambridge has closed a $7 million fundraising to commercialise its disease breathalyser.

The business was spun out of parent company, Owlstone Inc, by co-founder Billy Boyle to develop and commercialise the breath test for use in clinical diagnostics and precision medicine with applications in cancer, inflammatory and infectious disease.

The investment round was led by UK-based Medtekwiz Advisory and will be used to fund ongoing clinical trials of the breathalyser in lung and colon cancer screening.

Owlstone Medical was created to leverage proprietary and proven Field Asymmetric Ion Mobility Spectrometry (FAIMS) technology for the advancement of the breath test device.

FAIMS measures volatile organic compound (VOCs) metabolites in patient’s breath or bodily fluids which are specific to disease. Measurement of VOC biomarkers allows diagnosis of disease at a very early stage, to enable more effective treatment and better patient outcomes.

Owlstone Medical is managed by a highly experienced team and supported by world-renowned experts in lung cancer diagnosis. Billy Boyle, the CEO, is an engineering graduate from Cambridge University and one of the original co-founders of Owlstone Inc, which was spun out of the university in 2004 and has raised $28 million in investment and won over $25m in engineering grants – largely from the US Military.

Boyle said: “Securing this funding is further validation of our technology, and we are excited to progress our vision to revolutionise the detection and diagnosis of cancer, infectious and inflammatory diseases.

“The breathalyser we are developing provides clinicians with a highly sensitive, non-invasive diagnostic, which will enable early detection and improve patient outcomes.

“We are also working with pharma partners to develop non-invasive companion diagnostics to better match patients to treatment for emerging personalised therapies.”

Regius Professor Christofer Toumazou, advisor to Medtekwiz and recently appointed to the Owlstone Medical Board, said: “I am delighted to have joined the board and to be involved at such a milestone in the development of the Company.

“With the investment, I look forward to seeing a step change in the way serious disease can be diagnosed and monitored – particularly for colon and lung cancer, which are two of the biggest cancer killers worldwide.”

The potential of the technology to enable rapid detection of disease, without the need for costly, invasive medical procedures, saw Owlstone Medical win the Business Weekly Astra Zeneca-MedImmune Life Science Innovation award. That was mid-March and in the previous month the company won an NHS contract for STRATA, adapting the breathalyser technology for precision medicine and companion diagnostics.

Prior to that, it received a $1.4 million NHS contract for LuCID (Lung Cancer Indicator Detection) to use FAIMS technology in the early detection of lung cancer.


from Business Weekly

Veeva Systems – cloud-based software for the global life sciences industry

Veeva Systems’ healthcare professional and organization affiliations
data offering now spans most major markets and more than 19 million

Veeva Systems today announced the expansion of Veeva
customer reference and affiliations data to 12 Western
European countries and Canada. Veeva OpenData is now available in a
total of 32 countries, spanning more than 19 million practitioners and
representing more than 85% of global healthcare expenditures. With this
expansion, life sciences companies can rely on a single data provider in
all major markets for more targeted, compliant customer engagement. And
because data is priced by the record – with a defined-per country
maximum – companies now have fair pricing and a predictable cost of

“For too long, sales and marketing have been forced to purchase the same
data multiple times across teams and departments,” said Jim Cushman,
senior vice president and general manager of Veeva OpenData. “It’s our
aim to put an end to these exploitative practices. Companies purchase
Veeva OpenData just once and get comprehensive customer data, with
consistent quality, to use how and where they need it, without

Veeva OpenData provides rigorously verified and continuously updated
reference data for each country, drawing upon local market expertise,
while also delivering a standard, worldwide approach to data structure,
quality, customer service, and pricing. As a result, subscribers have
easy access to available healthcare professionals (HCPs), organizations
(HCOs), and affiliations data, in major life sciences markets worldwide.

With seamless integration to Veeva CRM, high-quality customer data is
readily accessible to commercial teams so they can better target
customers and tailor engagements – and do so far more efficiently.
Subscribers can engage in the right discussions, correctly track and
report aggregate spend, and ensure compliant activity with more accurate

“Reliable customer data has been notoriously difficult to obtain across
major countries, compromising compliance,” said Cushman. “Veeva OpenData
assures quality and completeness through stringent validation processes
in every one of the 32 countries Veeva serves. Taking this global
approach, Veeva OpenData can deliver a consistent standard for data
quality and customer service that is unmatched in the industry.”

Data change requests are a standard service included in subscriptions,
and most are resolved in less than one business day. Veeva also
introduced an industry first with its Veeva
OpenData Partner Program
, eliminating
the hassle of complicated three-party data access agreements. Freed to
fully leverage the customer data they purchase, companies can easily
share Veeva OpenData with any third party in an extensive partner

As of this month, Veeva OpenData is available in Australia, Austria,
Azerbaijan, Belarus, Belgium, Brazil, Canada, China, Denmark, Finland,
France, Georgia, Germany, Greece, Ireland, Italy, Japan, Kazakhstan,
Kyrgyzstan, Luxembourg, Moldova, The Netherlands, Norway, Portugal,
Russia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, the United
States, and Uzbekistan. The company will continue to expand Veeva
OpenData to additional countries throughout 2016.

For a complete Veeva OpenData global coverage map, click here.

Additional Information
For more on Veeva OpenData, visit:
updated on the latest Veeva news on LinkedIn:
@veevasystems on Twitter:
Veeva on Facebook:

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 375 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in the company’s filing on Form
10-Q for the period ended October 31, 2015. This is available on the
company’s website at
under the Investors section and on the SEC’s website at
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to

Veeva Systems Inc.
Sue Glanville, +44 (0) 7715 817589
Bonthuys, +44 (0) 7746 546773

Veeva Systems - cloud-based software for the global life sciences industry

Zambon – central nervous system therapeutics

  • Zambon is announcing today the availability and reimbursement on
    the Italian market of Xadago® (safinamide) as an add-on to levodopa
    alone or in combination with other Parkinson’s Disease (PD) medications
  • Xadago® (safinamide) is the result of the Italian research

Zambon S.p.A., an international pharmaceutical company strongly
committed to the central nervous system (CNS) therapeutic area, and its
partner Newron Pharmaceuticals S.p.A. (“Newron”), a research and
development company focused on novel CNS and pain therapies, today
announced the launch of Xadago® (safinamide) in Italy for the treatment
of mid- to late-stage Parkinson’s disease (PD). Following the launch in
Switzerland, Germany and Spain, Xadago® (safinamide) is now available in
Italy as add-on therapy to a stable dose of levodopa (L-dopa) alone or
in combination with other PD therapies for mid-to late-stage fluctuating
Zambon - newron - central nervous system therapeutics

Prof. Fabrizio Stocchi from IRCSS S. Raffaele, Rome, declared that “safinamide
represents an important option for patients with PD already treated with
L-dopa alone or with other therapeutic combinations. Its dopaminergic
and non dopaminergic properties introduce a novelty within the drugs for
PD treatment.”
Prof. Stocchi added: “Safinamide has been
demonstrated to significantly increase on time with no, or
non-troublesome dyskinesias in addition to an improvement of motor
functions (UPDRS III).
Studies performed in patients on L-Dopa
have demonstrated its efficacy in benefiting both short-term (6 months)
and long-term (up to 24 months) quality of life outcomes. Safinamide has
been investigated in double blind, placebo-controlled studies of up to
24 months’ duration, where it showed a good safety profile with
maintenance of the clinical benefits

Maurizio Castorina, CEO of Zambon S.p.A. said: “The launch of
Xadago® in Italy makes us particularly proud because it is the result of
Italian research excellence and a major step forward in the treatment of
this progressive disease. We are committed to developing innovative
therapies for patients suffering from PD and other central nervous
system diseases and we look forward to launching this new chemical
entity in other European countries in the near future.”

About Xadago® (safinamide)
Safinamide is a new chemical
entity with a unique mode of action including selective and reversible
MAO-B-inhibition and blocking of voltage dependent sodium channels which
leads to modulation of abnormal glutamate release. Clinical trials have
established its efficacy in controlling motor symptoms and motor
complications in the short term, maintaining this effect over 2 years.
Results from 24 month double-blind controlled studies suggest that
safinamide shows statistically significant effects on motor fluctuations
(ON/OFF time) without increasing the risk of developing troublesome
dyskinesia. This effect may be related to its dual mechanism acting on
both the dopaminergic and the glutamatergic pathways. Safinamide is a
once-daily dose and has no diet restrictions due to its high MAO-B/MAO-A
selectivity. The New Drug Application (NDA) for Xadago® to the US
FDA was accepted for filing by the US FDA, PDUFA date is March 29, 2016.
Zambon has the rights to develop and commercialize Xadago® globally,
excluding Japan and other key territories where Meiji Seika has the
rights to develop and commercialize the compound.

randomized, controlled study of safinamide as add-on to levodopa in mid
to late Parkinson’s disease.
Borgohain, Rupam; Szasz, Jozsef;
Stanzione, Paolo; Meshram, Chandrashekhar; Bhatt, Mohit H et al. (2014)
disorders : official journal of the Movement Disorder Society
29 (10) p. 1273-80.
Anand R: Safinamide is associated with
clinically important improvement in motor symptoms in fluctuating PD
patients as add-on to levodopa (SETTLE). 17th International Congress of
Parkinson’s Disease and Movement Disorders, Sydney, Australia, June
16-20, 2013.

About Parkinson’s disease
PD is the second most common
chronic progressive neurodegenerative disorder in the elderly after
Alzheimer’s disease, affecting 1-2% of individuals aged ≥ 65 years
worldwide. The prevalence of the PD market is expected to grow in the
next years due to the increase in the global population and advancements
in healthcare that contribute to an aging population at increased risk
for PD. The diagnosis of PD is mainly based on observational criteria of
muscular rigidity, resting tremor, or postural instability in
combination with bradykinesia. As the disease progresses, symptoms
become more severe. Early-stage patients are more easily managed on
L-dopa. L-dopa remains as the most effective treatment for PD, and over
75% of the patients with PD receive L-dopa. However, long term treatment
with L-dopa leads to seriously debilitating motor fluctuations, i.e.
phases of normal functioning (ON-time) and decreased functioning
(OFF-time). Furthermore, as a result of the use of high doses of L-dopa
with increasing severity of the disease, many patients experience
involuntary movements known as L-dopa-Induced Dyskinesia (LID). As the
disease progresses, more drugs are used as an add-on to what the patient
already takes, and the focus is to treat symptoms while managing LID and
the “off-time” effects of L-dopa. Most current therapies target the
dopaminergic system that is implicated in the pathogenesis of PD, and
most current treatments act by increasing dopaminergic transmission that
leads to amelioration of motor symptoms.

BMC Oertel. European Handbook of Neurological
Management, Vol1, Chapter 14 & 15, 2011.
NICE PD guideline,

About Zambon
Zambon is a leading Italian pharmaceutical and
fine-chemical multinational company that has earned a strong reputation
over the years for high quality products and services. Zambon is
well-established in 3 therapeutic areas: respiratory, pain and woman
care, and is very strongly committed to its entry into the CNS space.
Zambon S.p.A. produces high quality products thanks to the management of
the whole production chain which involves Zach (Zambon chemical), a
privileged partner for API, custom synthesis and generic products. The
Group is strongly working on the treatment of the chronic respiratory
diseases as asthma and BPCO and on the CNS therapeutic area with Xadago®
(safinamide) for the Parkinson treatment. Zambon is headquartered in
Milan and was established in 1906 in Vicenza. Zambon is present in 19
countries with subsidiaries and almost 2,700 employees with
manufacturing units in Italy, Switzerland, France, China and Brazil.
Zambon products are commercialized in 84 countries.

For details on Zambon please see:

About Newron Pharmaceuticals
Newron (SIX: NWRN) is a
biopharmaceutical company focused on the development of novel therapies
for patients with diseases of the central nervous system (CNS) and pain.
The Company is headquartered in Bresso near Milan, Italy. In addition to
Xadago® for Parkinson’s disease, Newron has a strong pipeline of
promising treatments for rare disease patients at various stages of
clinical development, including sarizotan for patients with Rett
syndrome and ralfinamide for patients with specific rare pain
indications. Newron is also developing NW-3509 as the potential first
add-on therapy for the treatment of patients with positive symptoms of
For more information, please visit:

Important Notices
This document contains forward-looking
statements, including (without limitation) about (1) Newron’s ability to
develop and expand its business, successfully complete development of
its current product candidates and current and future collaborations for
the development and commercialisation of its product candidates and
reduce costs (including staff costs), (2) the market for drugs to treat
CNS diseases and pain conditions, (3) Newron’s anticipated future
revenues, capital expenditures and financial resources, and (4)
assumptions underlying any such statements. In some cases these
statements and assumptions can be identified by the fact that they use
words such as “will”, “anticipate”, “estimate”, “expect”, “project”,
“intend”, “plan”, “believe”, “target”, and other words and terms of
similar meaning. All statements, other than historical facts, contained
herein regarding Newron’s strategy, goals, plans, future financial
position, projected revenues and costs and prospects are forward-looking

By their very nature, such statements and assumptions involve inherent
risks and uncertainties, both general and specific, and risks exist that
predictions, forecasts, projections and other outcomes described,
assumed or implied therein will not be achieved. Future events and
actual results could differ materially from those set out in,
contemplated by or underlying the forward-looking statements due to a
number of important factors. These factors include (without limitation)
(1) uncertainties in the discovery, development or marketing of
products, including without limitation negative results of clinical
trials or research projects or unexpected side effects, (2) delay or
inability in obtaining regulatory approvals or bringing products to
market, (3) future market acceptance of products, (4) loss of or
inability to obtain adequate protection for intellectual property
rights, (5) inability to raise additional funds, (6) success of existing
and entry into future collaborations and licensing agreements, (7)
litigation, (8) loss of key executive or other employees, (9) adverse
publicity and news coverage, and (10) competition, regulatory,
legislative and judicial developments or changes in market and/or
overall economic conditions.

Newron may not actually achieve the plans, intentions or expectations
disclosed in forward-looking statements and assumptions underlying any
such statements may prove wrong. Investors should therefore not place
undue reliance on them. There can be no assurance that actual results of
Newron’s research programmes, development activities, commercialisation
plans, collaborations and operations will not differ materially from the
expectations set out in such forward-looking statements or underlying

Newron does not undertake any obligation to publicly up-date or revise
forward looking statements except as may be required by applicable
regulations of the SIX Swiss Exchange where the shares of Newron are

This document does not contain or constitute an offer or invitation to
purchase or subscribe for any securities of Newron and no part of it
shall form the basis of or be relied upon in connection with any
contract or commitment whatsoever.
Contacts – Zambon – central nervous system therapeutics 

Luca Primavera – CCO, +39 02
Mobile: +39 335 7247417
Zambon Italy
Naguib, +39 02 66524095
Mobile: +39 3459215675
Zambon Newron
Weber – CEO, +39 02 6103 46 30
Julia Phillips, +44 (0)20 3727 1000
Martin Meier-Pfister, +41 43 244 81 40
Services AG
Anne Hennecke, +49 211 52925222
Zambon U.S.
Connolly, +1-617-374-8800, Ext. 108
and Analysts

Stefan Weber – CEO, +39 02 6103
46 30
Zambon Germany
Services AG
Anne Hennecke, +49 211 52925222
Connolly, +1-617-374-8800, Ext. 108

Zambon – central nervous system therapeutics